TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG Trademark

Trademark Overview

On Wednesday, September 21, 2016, a trademark application was filed for TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG with the United States Patent and Trademark Office. The USPTO has given the TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG trademark a serial number of 87178937. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, November 27, 2020. This trademark is owned by GENENTECH, INC.. The TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Providing online information services, namely, prescription drug information in relation to the treatment and symptoms of disorders relating to oncology, autoimmune, or inflammatory diseases
tecentriq atezolizumab injection for intravenous use 1200 mg

General Information

Serial Number87178937
Word MarkTECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG
Filing DateWednesday, September 21, 2016
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateFriday, November 27, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 3, 2018

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Disclaimer with Predetermined Text"ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG"
Description of MarkThe mark consists of the wording "TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG" in stylized font, wherein three arrows pointing inwards appears in the upper left of the wording "TECENTRIQ".
Goods and ServicesProviding online information services, namely, prescription drug information in relation to the treatment and symptoms of disorders relating to oncology, autoimmune, or inflammatory diseases

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, September 27, 2016
Primary Code044
First Use Anywhere DateWednesday, May 18, 2016
First Use In Commerce DateWednesday, May 18, 2016

Trademark Owner History

Party NameGENENTECH, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSOUTH SAN FRANCISCO, CA 940804990
Party NameGENENTECH, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSOUTH SAN FRANCISCO, CA 940804990

Trademark Events

Event DateEvent Description
Friday, April 23, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, April 23, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, April 23, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, April 23, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, November 27, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Friday, November 27, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Friday, May 15, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, May 15, 2020FINAL REFUSAL E-MAILED
Friday, May 15, 2020SU - FINAL REFUSAL - WRITTEN
Thursday, May 14, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 13, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 13, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 18, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 18, 2019NON-FINAL ACTION E-MAILED
Monday, November 18, 2019SU - NON-FINAL ACTION - WRITTEN
Saturday, November 16, 2019STATEMENT OF USE PROCESSING COMPLETE
Wednesday, November 6, 2019USE AMENDMENT FILED
Saturday, November 16, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 6, 2019TEAS STATEMENT OF USE RECEIVED
Wednesday, May 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 6, 2019EXTENSION 2 GRANTED
Monday, May 6, 2019EXTENSION 2 FILED
Monday, May 6, 2019TEAS EXTENSION RECEIVED
Wednesday, November 7, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 5, 2018EXTENSION 1 GRANTED
Monday, November 5, 2018EXTENSION 1 FILED
Monday, November 5, 2018TEAS EXTENSION RECEIVED
Tuesday, May 29, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 3, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 3, 2018PUBLISHED FOR OPPOSITION
Wednesday, March 14, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 28, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 13, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 13, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 12, 2018ASSIGNED TO LIE
Monday, February 5, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 3, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 3, 2017NON-FINAL ACTION E-MAILED
Thursday, August 3, 2017NON-FINAL ACTION WRITTEN
Wednesday, August 2, 2017PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, July 25, 2017WITHDRAWN FROM PUB - OG REVIEW QUERY
Monday, July 3, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, June 23, 2017EXAMINER'S AMENDMENT ENTERED
Friday, June 23, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, June 23, 2017EXAMINERS AMENDMENT E-MAILED
Friday, June 23, 2017EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 4, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 4, 2017NON-FINAL ACTION E-MAILED
Wednesday, January 4, 2017NON-FINAL ACTION WRITTEN
Wednesday, December 28, 2016ASSIGNED TO EXAMINER
Wednesday, September 28, 2016NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, September 27, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, September 24, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

intravenous injection atezolizumab tecentriq information relating disorders oncology inflammatory diseases symptoms autoimmune relation services